Assessing the cost‐effectiveness of sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real‐world evidence
Year: 2020
Type: article
Source: Diabetes Obesity and Metabolism
DOI: 10.1111/dom.14162
Authors: Phil McEwan, Hayley Bennett, Kamlesh Khunti, John Wilding, Christopher Edmonds, Marcus Thuresson, Eric Wittbrodt, Peter Fenici, Mikhail Kosiborod
Institutions: Health Economics and Outcomes Research (United Kingdom), University of Leicester, Leicester General Hospital, Aintree University Hospital, AstraZeneca (United States), Statisticon (Sweden), AstraZeneca (United Kingdom), UNSW Sydney, The George Institute for Global Health, Saint Luke's Hospital, University of Missouri–Kansas City
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: AstraZeneca
OpenAlex ID: W3046450221